Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12841880 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL764187 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL5750970 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL10130026 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL10155799 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL764132 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL12322681 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2515302 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL6823616 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL13567843 | 0.91 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116115764-A | Tetrahydroimidazo [4,5-C ] pyridine derivatives as PD-L1 internalization inducers | 因赛特公司 | 2023-05-16 | — | — | CN | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0687249-A1 | BALANOIDS | ELI LILLY AND COMPANY (US) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | SMN1; SMN2 4556/4885NPC1 499/4885RAB9A 2169/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | SMN1; SMN2 4495/4885NPC1 424/4885RAB9A 1280/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | SMN1; SMN2 4177/4885NPC1 945/4885RAB9A 2399/4885 |
| US-11787793-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | SMN1; SMN2 4177/4885NPC1 945/4885RAB9A 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.